ANGLE plc - Asset Resilience Ratio
ANGLE plc (AGL) has an Asset Resilience Ratio of 33.24% as of June 2021. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read debt load of ANGLE plc for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2004–2020)
This chart shows how ANGLE plc's Asset Resilience Ratio has changed over time. See AGL total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down ANGLE plc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is ANGLE plc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | GBX0.00 | 0% |
| Short-term Investments | GBX11.55 Million | 33.24% |
| Total Liquid Assets | GBX11.55 Million | 33.24% |
Asset Resilience Insights
- Very High Liquidity: ANGLE plc maintains exceptional liquid asset reserves at 33.24% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ANGLE plc Industry Peers by Asset Resilience Ratio
Compare ANGLE plc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 6.56% |
|
Inoviq Ltd
AU:IIQ |
Diagnostics & Research | 56.29% |
|
Bcal Diagnostics Ltd
AU:BDX |
Diagnostics & Research | 0.00% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
|
Integral Diagnostics Ltd
AU:IDX |
Diagnostics & Research | 0.03% |
|
Australian Clinical Labs Ltd
AU:ACL |
Diagnostics & Research | 4.11% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
Annual Asset Resilience Ratio for ANGLE plc (2004–2020)
The table below shows the annual Asset Resilience Ratio data for ANGLE plc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-12-31 | 42.35% | GBX16.54 Million ≈ $2.01K |
GBX39.05 Million ≈ $4.75K |
-6.74pp |
| 2019-12-31 | 49.09% | GBX15.01 Million ≈ $1.83K |
GBX30.57 Million ≈ $3.72K |
+27.82pp |
| 2013-04-30 | 21.27% | GBX1.60 Million ≈ $194.67 |
GBX7.52 Million ≈ $915.31 |
+24.24pp |
| 2012-04-30 | -2.97% | GBX-154.00K ≈ $-18.74 |
GBX5.18 Million ≈ $630.86 |
+25.58pp |
| 2011-04-30 | -28.55% | GBX-1.50 Million ≈ $-182.51 |
GBX5.25 Million ≈ $639.26 |
+0.12pp |
| 2010-04-30 | -28.67% | GBX-1.55 Million ≈ $-188.47 |
GBX5.40 Million ≈ $657.39 |
-37.83pp |
| 2009-04-30 | 9.16% | GBX499.00K ≈ $60.71 |
GBX5.45 Million ≈ $663.11 |
-2.19pp |
| 2008-04-30 | 11.35% | GBX1.04 Million ≈ $126.78 |
GBX9.18 Million ≈ $1.12K |
-12.05pp |
| 2007-04-30 | 23.40% | GBX1.81 Million ≈ $220.47 |
GBX7.74 Million ≈ $941.98 |
-6.79pp |
| 2006-04-30 | 30.20% | GBX4.87 Million ≈ $592.29 |
GBX16.12 Million ≈ $1.96K |
0.00pp |
| 2005-04-30 | 30.20% | GBX4.87 Million ≈ $592.29 |
GBX16.12 Million ≈ $1.96K |
+10.31pp |
| 2004-04-30 | 19.89% | GBX2.40 Million ≈ $291.77 |
GBX12.06 Million ≈ $1.47K |
-- |
About ANGLE plc
ANGLE plc, a medical diagnostic company, develops cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ C… Read more